Crawford four-month appraisal
This article was originally published in The Tan Sheet
Executive Summary
Acting FDA Commissioner Lester Crawford, PhD, "is doing an awesome job," HHS Secretary Tommy Thompson tells AdvaMed board members June 20 in Washington, D.C. "He is out there to make changes. He is already making more changes in the short couple [of] months he's been here...realigning, reorganizing, putting in the risk assessment system....Whether or not he's going to get to be the commissioner I can't tell you. That's a decision for the President. But I can assure you, until the final commissioner is appointed by the President, this man is in charge, this man is going to continue to make changes"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.